Real-World Effectiveness and Safety of Evinacumab in Children and Adults With Homozygous Familial Hypercholesterolemia: A Multisite US Perspective—Brief Report
Arteriosclerosis, Thrombosis, and Vascular Biology · 2025
DOI: 10.1161/atvbaha.124.322364 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2025. Verfasst von Michael J Wilkinson und 11 weiteren Autor:innen. Beteiligte Einrichtung: University of California San Diego, La Jolla (M.J.W., P.B., R.S.N.). Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Anticholesteremic Agents, Cholesterol, LDL. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
BACKGROUND: Homozygous familial hypercholesterolemia (HoFH) is an autosomal semidominant disorder characterized by extreme elevations in LDL-C (low-density lipoprotein cholesterol) and early-onset atherosclerotic cardiovascular disease. Evinacumab is a monoclonal antibody administered by monthly intravenous infusion that binds ANGPTL3 (angiopoietin-like 3) and when added to standard lipid-lowering therapies lowers LDL-C by ≈50% in HoFH clinical trials. Studies examining the real-world effectiveness and safety of evinacumab are limited. METHODS: We performed a retrospective study to assess the effectiveness and safety of evinacumab in patients with HoFH in clinical practice at 6 US academic medical centers. The primary end point was the percent change in LDL-C from baseline to first follow-up and to the most recent follow-up after evinacumab initiation. Secondary end points were percent change in non–high-density lipoprotein cholesterol (non–HDL-C), triglycerides, total cholesterol, HDL-C, and achievement of an LDL-C
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of California San Diego, La Jolla (M.J.W., P.B., R.S.N.).
- University of Chicago, IL (M.H.D., M.H., P.P.).
- Oregon Health & Science University, Portland (P.B.D., B.A.W.).
- University of California San Francisco (M.J.M., E.O.S.).
- Rady Children's Hospital, San Diego, CA (R.S.N.).
- Cedars-Sinai Medical Center, Los Angeles, CA (P.K.S.).
ORCID-Profile: Michael J Wilkinson, Priyesha Bijlani, P Barton Duell, Mary J Malloy, Ron S Newfield, Eveline O Stock, Bruce A Warden
Zitieren
APA
Wilkinson, M. J., Bijlani, P., Davidson, M. H., Duell, P. B., Horan, M., Malloy, M. J., Newfield, R. S., Pradeep, P., Shah, P. K., Stock, E. O., Warden, B. A., & Ito, M. K. (2025). Real-World Effectiveness and Safety of Evinacumab in Children and Adults With Homozygous Familial Hypercholesterolemia: A Multisite US Perspective—Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.124.322364
Vancouver
Wilkinson MJ, Bijlani P, Davidson MH, Duell PB, Horan M, Malloy MJ, et al. Real-World Effectiveness and Safety of Evinacumab in Children and Adults With Homozygous Familial Hypercholesterolemia: A Multisite US Perspective—Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology. 2025. doi:10.1161/atvbaha.124.322364
BibTeX
@article{Wilkinson2025,
author = {Wilkinson, Michael J and Bijlani, Priyesha and Davidson, Michael H and Duell, P Barton and Horan, Mary and Malloy, Mary J and Newfield, Ron S and Pradeep, Pallavi and Shah, Prediman K and Stock, Eveline O and Warden, Bruce A and Ito, Matthew K},
title = {Real-World Effectiveness and Safety of Evinacumab in Children and Adults With Homozygous Familial Hypercholesterolemia: A Multisite US Perspective—Brief Report},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2025},
doi = {10.1161/atvbaha.124.322364}
}
EUVIMED